# Effect of de-worming on physical fitness of school-aged children in Yunnan, China

Submission date 14/09/2011	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
Registration date 15/11/2011	<b>Overall study status</b> Completed	<ul> <li>Statistical analysis plan</li> <li>[X] Results</li> </ul>
Last Edited 17/09/2013	<b>Condition category</b> Infections and Infestations	Individual participant data

#### Plain English summary of protocol

Background and study aims:

The most common parasitic worms that affect humans are the roundworm, whipworm and hookworm. Humans can be infected by eating food contaminated with the eggs of these parasitic worms or if the worms penetrate the skin. Parasitic worm infections can cause reduced growth rate (stunting) and wasting in school-aged children, and it is also possible that these parasitic worms reduce their physical fitness and strength.

The aim of this study is to determine whether de-worming has an effect on the physical fitness and strength of school-aged children in south-western Yunnan, China.

#### Who can participate?

Primary school children, aged 9-12 years, who are infected with one or more species of parasitic worms, but do not have major systemic illnesses.

#### What does the study involve?

The participants were subjected to tests to see if they are infected by parasitic worms, and were required to provide stool samples for analysis. Measurements of the participants weight, height and skinfolds were taken, as well as assessments on their performance in a 20m shuttle run, grip strength and standing broad jump tests. The participants randomly allocated to two groups to receive either albendazole or placebo (a dummy drug). The examinations were carried out before, during and after the participants were given treatment with albendazole or placebo.

What are the possible benefits and risks of participating?

Those in the albendazole group will no longer be infected with parasitic worms. Those who were not, would still benefit as all participants were given a single dose of albendazole free of charge at the end of the study. There were no known risks associated with taking part in this study.

Where is the study run from?

Rural primary schools in Menghai County, Xishuangbanna Dai, Yunnan province, China.

When is the study starting and how long is it expected to run for? The study started in October 2011 and ran for approximately 8 months. Who is funding the study? Swiss Tropical and Public Health Institute, Switzerland.

Who is the main contact? Prof Jürg Utzinger juerg.utzinger@unibas.ch

## **Contact information**

**Type(s)** Scientific

**Contact name** Prof Juerg Utzinger

**Contact details** Department of Epidemiology and Public Health Swiss Tropical and Public Health Institute Basel Switzerland 4002 +41 (0)61 284 8129 juerg.utzinger@unibas.ch

## Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers N/A

## Study information

#### Scientific Title

Effect of de-worming on physical fitness of school-aged children in Yunnan, China: a doubleblind, randomised, placebo-controlled trial

**Study objectives** De-worming can improve the physical fitness and strength of school-aged children

**Ethics approval required** Old ethics approval format

#### Ethics approval(s)

1. Ethics Committee of Basel (Ethikkommission beider Basel) (EKBB, Switzerland; reference no. 144/11) approved on 9 May 2011 (original proposal) and 16 August 2011 (amendment)

2. Academic Board of the National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (IPD/China CDC) approved on 25 April 2011

#### Study design

Double-blind randomised placebo-controlled trial

**Primary study design** Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Other

#### Study type(s)

Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

#### Health condition(s) or problem(s) studied

Soil-transmitted helminth infections

#### Interventions

Participants who were diagnosed with soil-transmitted helminths at the baseline parasitological examination will be randomly allocated to the following treatment arms: Treatment arm 1: triple-dose albendazole (400 mg daily for 3 consecutive days) Treatment arm 2: triple-dose placebo (single dose daily for 3 consecutive days)

#### Intervention Type

Other

**Phase** Not Applicable

#### Primary outcome measure

Changes in physical fitness and strength

#### Secondary outcome measures

1. Reduction of infection prevalence and intensity of soil-transmitted helminths and subsequent re-infection pattern

2. Changes in anthropometric and haemoglobin measurements

#### Overall study start date

17/10/2011

Completion date 25/06/2012

## Eligibility

#### Key inclusion criteria

1. Primary school child, aged 9-12 years, male or female

- 2. Written informed consent by a parent / guardian on behalf of the child
- 3. Submission of two stool samples at baseline
- 4. Completion of anthropometric and haemoglobin measurements at baseline
- 5. Completion of 20 m shuttle run test at baseline

6. Completion of grip strength test and standing broad jump test at baseline

7. Infected with one or more common soil-transmitted helminths (Ascaris lumbricoides, Trichuris trichuria, hookworm)

8. Absence of major systemic illnesses, as assessed by a medical doctor at baseline

9. No known or reported drug allergy to albendazole

10. Treatment with albendazole (or matching placebo)

11. Anticipated residence in the study area for at least 1 year

#### Participant type(s)

Patient

### Age group

Child

#### Lower age limit

9 Years

#### Upper age limit

12 Years

#### Sex

Both

#### Target number of participants

250

#### Key exclusion criteria

- 1. Children below the age of 9 years or above 12 years
- 2. No written informed consent

3. Less than 2 stool samples submitted at baseline

4. Presence of medical condition that prevents child from completing the physical fitness and strength tests

- 5. Known or reported drug allergy to albendazole
- 6. Absence/refusal of albendazole treatment (or matching placebo)

7. Attending other clinical trials during the study period

#### Date of first enrolment

17/10/2011

#### Date of final enrolment

25/06/2012

## Locations

**Countries of recruitment** China

Switzerland

**Study participating centre Department of Epidemiology and Public Health** Basel Switzerland 4002

## Sponsor information

**Organisation** Swiss Tropical and Public Health Institute (Switzerland)

**Sponsor details** Socinstrasse 57 Basel Switzerland 4002

#### Sponsor type Government

Website http://www.swisstph.ch/

ROR https://ror.org/03adhka07

## Funder(s)

**Funder type** Government

**Funder Name** Swiss Tropical and Public Health Institute (Switzerland)

## **Results and Publications**

#### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

#### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	results	01/07/2013		Yes	No